Scott N. Boyle - 07 Mar 2024 Form 4 Insider Report for C4 Therapeutics, Inc. (CCCC)

Role
Chief Business Officer
Signature
/s/ Jolie M. Siegel, Attorney-in-Fact
Issuer symbol
CCCC
Transactions as of
07 Mar 2024
Net transactions value
$0
Form type
4
Filing time
08 Mar 2024, 19:28:56 UTC
Previous filing
15 Feb 2024
Next filing
17 Sep 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CCCC Stock Option (Right to Buy) Disposed to Issuer $0 -115,000 -100% $0.000000* 0 07 Mar 2024 Common Stock 115,000 $33.23 Direct F1, F2
transaction CCCC Stock Option (Right to Buy) Award $0 +115,000 $0.000000 115,000 07 Mar 2024 Common Stock 115,000 $19.00 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On March 7, 2024, the Compensation Committee of the Issuer's Board of Directors approved an option repricing. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.
F2 25% of the shares underlying this option shall vest and become exercisable on January 3, 2023, with the remainder vesting in twelve equal quarterly installments thereafter.